We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01355588
First Posted: May 18, 2011
Last Update Posted: March 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Egalet Ltd
  Purpose

This was a phase 1, double-blind, 4-way crossover study in healthy male and female volunteers. Subjects received 4 formulations of intranasal ketorolac tromethamine 30 mg. There was a wash-out period of 3-7 days between each dose. On Day 1 of each period subjects were randomised to receive either a single intranasal dose of 30 mg ketorolac tromethamine alone or single intranasal dose of 30 mg ketorolac tromethamine with 4%, 5% or 6% lidocaine hydrochloride. At the end of the study each subject had received all 4 treatments.

The primary objective of this study in healthy volunteers was to compare the safety, tolerability, and pharmacokinetics of 4 formulations of ketorolac tromethamine. A secondary objective was to monitor lidocaine hydrochloride plasma levels.


Condition Intervention Phase
Healthy Volunteers Drug: Ketorolac Tromethamine Drug: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl) Drug: Ketorolac Tromethamine with 5% Lidocaine HCl Drug: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Double-blind, 4-way Crossover Study of the Tolerability, Safety and Pharmacokinetics of 4 Formulations of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Egalet Ltd:

Primary Outcome Measures:
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Anytime at pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours (ketorolac tromethamine only), and 24 hours (ketorolac tromethamine only) post-dose ]
  • Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Post-dose (AUC 0-t) [ Time Frame: Anytime at pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours (ketorolac tromethamine only), and 24 hours (ketorolac tromethamine only) post-dose ]
  • Area Under the Plasma Concentration-time Profile From Time Zero to Infinity (AUC 0-∞) [ Time Frame: Anytime at pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours (ketorolac tromethamine only), and 24 hours (ketorolac tromethamine only) post-dose ]

Secondary Outcome Measures:
  • Time to Reach Maximum Plasma Concentration (Tmax) [ Time Frame: Anytime at pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours (ketorolac tromethamine only), and 24 hours (ketorolac tromethamine only) post-dose ]

Enrollment: 16
Study Start Date: August 2005
Study Completion Date: March 2006
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ketorolac Tromethamine Drug: Ketorolac Tromethamine
30 mg Ketorolac Tromethamine intranasal (IN)
Experimental: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl) Drug: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)
30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
Experimental: Ketorolac Tromethamine with 5% Lidocaine HCl Drug: Ketorolac Tromethamine with 5% Lidocaine HCl
30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
Experimental: Ketorolac Tromethamine with 6% Lidocaine HCl Drug: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl
30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female volunteers, aged 18 to 60 years inclusive
  • Female subjects of child bearing potential must have had a negative urine pregnancy test prior to entry into the study and must not have been breast feeding
  • All female subjects of child bearing potential and all male subjects with female partners of child bearing potential must have consented to use a medically acceptable method of contraception (oral or implanted contraceptive hormones, condom or diaphragm with spermicidal agent, intrauterine device or surgical sterilisation) throughout the study period
  • Subject had given signed informed consent
  • Subject was within 20% of normal weight for his/her height and body build according to the table of "Desirable Weights for Men and Women" (Metropolitan Life Insurance Co. 1999)
  • Subject's medical history was considered normal, with no clinically significant abnormalities
  • Subject was considered to be in good health in the opinion of the Investigator as determined by a pre-study physical examination with no clinically significant abnormalities, vital signs within normal range and an ECG with no clinically significant abnormalities
  • Subject's pre-study clinical laboratory findings were within normal range or, if outside of the normal range, not deemed clinically significant in the opinion of the Investigator
  • Subject had bilateral patent nasal airways at screening as assessed by the Investigator
  • Body weight was at least 70 kg

Exclusion Criteria:

  • Subject had a clinically significant illness in the 4 weeks before screening
  • Use of prescribed medications in the 3 weeks prior to dosing or over-the-counter preparations for 7 days prior to dosing, except paracetamol which was allowed up to 48 hours prior to dosing. However, use of multivitamins and oral contraceptives were permitted
  • Subject had a significant history of drug/solvent abuse, or a positive drugs of abuse test at screening
  • Subject had history of alcohol abuse or drank in excess of 28 units per week (males) or 21 units per week (females)
  • Current tobacco use or a history of smoking within the past 5 years
  • Subject was, in the opinion of the Investigator, not suitable to participate in the study
  • Subjects who had participated in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Subjects who had a positive result of HIV screen, Hepatitis B screen or Hepatitis C screen
  • Subjects with a serious adverse reaction or significant hypersensitivity to any drug
  • Subjects who has donated 500 mL or more of blood within the 3 months prior to screening
  • Any history of co-existing nasal polyps, NSAID sensitivity and asthma
  • Allergic reaction to aspirin or other NSAIDs
  • Current upper respiratory tract infection or other respiratory tract condition that could have interfered with the absorption of the nasal spray or with the assessment of AEs
  • Any suspicion of rhinitis medicamentosa (chronic daily use of topical decongestants)
  • Use of a monoamine oxidase inhibitor in the 14 days prior to study entry
  • Active peptic ulcer disease, gastrointestinal bleeding or perforation, or a history of peptic ulcer disease or gastrointestinal bleeding
  • Anemia due to unexplained or known gastrointestinal bleeding
  • History of asthma or any other chronic pulmonary disorder
  • Renal impairment or a risk of renal failure due to volume depletion
  • Known sensitivity to lidocaine hydrochloride
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01355588


Locations
United Kingdom
Medeval Ltd
Manchester, United Kingdom
Sponsors and Collaborators
Egalet Ltd
Investigators
Principal Investigator: Cyril Clarke, BSc MB BS MFPM Medeval Limited
  More Information

Responsible Party: Egalet Ltd
ClinicalTrials.gov Identifier: NCT01355588     History of Changes
Other Study ID Numbers: ROX 2005-02
First Submitted: May 16, 2011
First Posted: May 18, 2011
Results First Submitted: November 16, 2012
Results First Posted: May 3, 2013
Last Update Posted: March 16, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Lidocaine
Ketorolac
Ketorolac Tromethamine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors